Serina Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 25, 2026
SER$1.43+3.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(In thousands, except per share data)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| REVENUES | ||
| Grant revenues | $130 | $56 |
| Total revenues | 130 | 56 |
| OPERATING EXPENSES | ||
| Research and development | 13,155 | 7,480 |
| General and administrative | 10,997 | 9,624 |
| Total operating expenses | 24,152 | 17,104 |
| Loss from operations | (24,022) | (17,048) |
| OTHER INCOME, NET | ||
| Interest expense | (213) | (526) |
| Change in fair value of convertible promissory notes | — | (7,017) |
| Change in fair value of warrants liabilities | 4,263 | 13,156 |
| Gain on warrants expiration | 724 | — |
| Other income, net | 51 | 228 |
| Total other income, net | 4,825 | 5,841 |
| Loss before income taxes | (19,197) | (11,207) |
| Provision for income taxes | (18) | — |
| NET LOSS | (19,215) | (11,207) |
| Net loss attributable to noncontrolling interest | 33 | 66 |
| NET LOSS ATTRIBUTABLE TO SERINA | $(19,182) | $(11,141) |
| NET LOSS ATTRIBUTABLE TO SERINA COMMON STOCKHOLDERS | $(19,436) | $(11,141) |
| NET LOSS ATTRIBUTABLE TO SERINA COMMON SHAREHOLDER, BASIC AND DILUTED | $(1.91) | $(1.51) |
| WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING, BASIC AND DILUTED | 10,190 | 7,359 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.